Drug Trial Radar · NCT06076304
Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis
Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,720
Planned (sponsor's estimate)
Start
Nov 21, 2023
Primary completion
Oct 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Daniel MerensteinAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Patient-Centered Outcomes Research Institute; Medstar Health Research Institute; University of Washington; Virginia Commonwealth University; University of California, Los Angeles; University of Wisconsin, Madison; Penn State College of Medicine
- First posted
- Oct 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Sinus infections (also called acute rhinosinusitis or ARS) affect about 15% of adults each year, and are one of the top reasons people receive antibiotics in outpatient settings. Since most sinus infections are caused by viruses, many patients who take antibiotics for this condition do not actually benefit. Even though this has decreased over recent years, 70% of people are still prescribed them after a visit for ARS. Our goal is to better understand which patients truly benefit from antibiotics and which other treatment options can help people with sinus infections.
Conditions
- Sinus Infection
- Acute Sinusitis
Interventions
amoxicillin/clavulanate potassiumDrug
Amoxicillin/clavulanate, oral, 875mg/125mg twice daily for 7 days
PlaceboDrug
Placebo for amoxicillin/clavulanate, oral, twice daily for 7 days
Budesonide nasal sprayDrug
Budesonide nasal spray, 32 mcg per spray, 2 sprays per nostril, once per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Symptom ImprovementTime frame: Change from Day 1 to Day 3 in Phase 2; differences in longitudinal trends across groups during Phase 2
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
University of California, Los Angeles
Los Angeles, California · Recruiting
Georgetown University Medical Center
Washington D.C., District of Columbia · Recruiting
MedStar Health Research Institute
Hyattsville, Maryland · Not yet recruiting
Penn State College of Medicine
Hershey, Pennsylvania · Recruiting
Virginia Commonwealth University
Richmond, Virginia · Recruiting
University of Washington
Seattle, Washington · Recruiting
University of Wisconsin-Madison
Madison, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.